AA
RAPP

ALPS Advisors’s Rapport Therapeutics RAPP Stock Holding History

ALPS Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
48,243
+9,336
+24% +$343K 0.01% 520
2026
Q1 		$1.22M Sell
38,907
-232
-0.6% -$6.53K 0.01% 547
2025
Q4 		$1.19M Buy
39,139
+22,037
+129% +$610K 0.01% 502
2025
Q3 		$508K Sell
17,102
-2,610
-13% -$46.6K ﹤0.01% 661
2025
Q2 		$224K Sell
19,712
-6,416
-25% -$68.1K ﹤0.01% 1000
2025
Q1 		$262K Sell
26,128
-3,452
-12% -$44.8K ﹤0.01% 938
2024
Q4 		$525K Buy
+29,580
New +$655K ﹤0.01% 595

Other funds holding RAPP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors's RAPP Position: Q2 2026 in Review

ALPS Advisors increased its Rapport Therapeutics (RAPP) stake by 24% in Q2 2026, buying an estimated $343K and bringing the position to 48,243 shares worth $2.01M. The position accounts for 0.01% of the portfolio, ranked #520.

ALPS Advisors first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 47 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • ALPS Advisors held 48,243 shares of Rapport Therapeutics worth $2.01M as of Q2 2026.
  • ALPS Advisors bought 9,336 Rapport Therapeutics shares in Q2 2026, an estimated $343K.
  • Rapport Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #520 holding.
  • ALPS Advisors first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 47 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.